Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of 2nd Gen vs 1st Gen Buprenorphine Patch in Healthy Volunteers
NCT02268422Phase 1Completed
- Sponsor
- Mundipharma
- Start
- Oct 2014
- Primary completion
- Dec 2014
- Modality
- Orthosteric Ligands, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of v1003 in pain (2 arms), sponsored by Mundipharma. Primary endpoints: Bioequivalence up to 288 hours and Patch adhesion at 168 hours. Started Oct 2014; status: completed.
02
Drugs
v1003
03
Conditions
pain
Beyond the preview
Go deeper on NCT02268422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02268422.